Khaled E. Abuelella

Dr. Khaled E. Abuelella

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2025 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Open access
PDF file
Khaled E. AbuelellaKhaled E. Abuelella
Khaled E. Abuelella
SMShimaa Mosalm
Shimaa Mosalm
AEAmira A. El-Gazar
Amira A. El-Gazar
AEAhmed Elshafeey
Ahmed Elshafeey
SSSara M. Soliman
Sara M. Soliman
Purpose: Polycaprolactone nanoparticles (PCLNPs) are biodegradable carriers widely investigated for drug delivery applications. Their hydrophobic nature and high encapsulation efficiency make them ideal for sustained drug release. This study aimed to encapsulate licofelone (LF), a dual COX/5-LOX inhibitor, within PCLNPs to enhance its therapeutic efficacy for osteoarthritis treatment through transdermal administration. Methods: LF loaded PCLNPs were formulated using the nanoprecipitation method. A 2 3 full factorial design was employed by varying PCL (100 or 150 mg), PVA (150 or 300 mg), and SDC (10 or 20 mg) at two levels each. The optimum formula was F8, consisting of 150 mg PCL, 300 mg PVA, and 20 mg SDC. Results: F8 formulation exhibited a spherical shape with a particle size (PS) of 269.3 ± 1.90 nm, an encapsulation efficiency (EE%) of 89 ± 0.56%, a polydispersity index (PDI) of 0.21 ± 0.02, and a zeta potential (ZP) of -27.85 ± 0.07 mV. The F8 gel exhibited a sustained-release profile, with drug permeation across excised rat skin 2.47-fold higher than that of the LF gel ( n = 3, p < 0.05). In vivo evaluation revealed significant chondroprotective and regenerative effects in a monoiodoacetate (MIA)-induced osteoarthritis rat model. F8 gel suppressed the release of inflammatory and pain mediators (5-LOX, COX, LTB 4 , and PGE2) and serum cartilage degradation products (CTX-II and COMP) after 10 days of treatment. Histological evaluation further confirmed its ability to prevent cartilage surface depletion and matrix loss. Conclusion: The optimized F8 gel achieved sustained LF release for approximately 20 h, enhanced ex vivo permeation by 2.47-fold relative to LF gel, and significantly reduced inflammatory mediators and cartilage degradation markers in vivo, highlighting its potential as a promising transdermal therapy for osteoarthritis management. Graphical

10 July 2025 in International Journal of Cosmetic Science
Verified
Journal Article
Closed access
Khaled E. AbuelellaKhaled E. Abuelella
Khaled E. Abuelella
SGSaadalla Nady Gaid
Saadalla Nady Gaid
MKMahmoud Alaaeldin Khattab
Mahmoud Alaaeldin Khattab
KRKareem O. Rashwan
Kareem O. Rashwan
NSNermin M. Sheta
Nermin M. Sheta

5 April 2025 in Bulletin of Pharmaceutical Sciences Assiut University
Verified
Journal Article
Closed access
Khaled E. AbuelellaKhaled E. Abuelella
Khaled E. Abuelella
SMShaimaa Mosallam
Shaimaa Mosallam
SSSara M. Soliman
Sara M. Soliman
AEAhmed Hassen Elshafeey
Ahmed Hassen Elshafeey
The management of skin wounds resulting from trauma and different pathophysiological diseases still presents a major challenge in healthcare, which greatly contributes to the worldwide economic burden. Recently, wound dressings based in nanotechnology and polymeric systems have emerged as a viable option to improve the healing process. Natural Biodegradable polymers, which include collagen, cellulose, chitosan (CS), and hyaluronic acid (HA), have shown high biocompatibility and efficacy in promoting wound healing. Despite these advantages, wound dressings made of biodegradable synthetic polymers provide a promising alternative by overcoming the limitations of natural polymers and displaying desired properties for skin wound treatment. The synthetic polymers include polycaprolactone (PCL), polyvinyl alcohol (PVA), poly (lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polyurethane (PU), polyethylene glycol (PEG), polyethylene oxide (PEO), and polyglycolic acid (PGA). These polymers are biocompatible, present a versatile chemical structure, and are easily modified to obtain distinct mechanical properties and degradation rates. Overall, these polymers are less expensive than natural polymers. This review outlines the optimal management and care required for wound treatment with a special focus on natural and synthetic biopolymers, drug-delivery systems, and nanotechnologies used for enhanced wound-healing applications

12 February 2025 in Bulletin of Pharmaceutical Sciences Assiut University
Verified
Journal Article
Closed access
Khaled E. AbuelellaKhaled E. Abuelella
Khaled E. Abuelella
MFMohamed Adel Fakher
Mohamed Adel Fakher
HMHassan Gamal Mostafa
Hassan Gamal Mostafa
OEOmar Mohamed ElRakabawy
Omar Mohamed ElRakabawy
Wound healing is a complex physiological process that repairs tissue integrity with stages including hemostasis, inflammation, proliferation, and remodeling. The primary aim of wound management is to avert infection, limit necrotic tissue development, expedite the healing process, and reduce scar formation. Chitosan (CS) is a biopolymer that has been extensively studied for its potential use in wound healing applications. This is due to its biocompatibility, biodegradability, non-toxicity, antimicrobial, haemostatic, and analgesic properties. Protection against bacteria, algae, and fungi is the source of its antimicrobial properties. Chemical modifications have improved the haemostatic activity and analgesic properties of the CS, which enhance patient comfort during the recovery phase. Furthermore, CS and its derivative have attracted much attention due to the accelerated wound healing. This review examines the synthesis, structural characteristics, and inherent properties of CS, as well as its potential applications in wound treatment, with a focus on antimicrobial efficacy, haemostatic capabilities, analgesic effects, and relevant clinical studies.

3 August 2025 in Bulletin of Pharmaceutical Sciences Assiut University
Verified
Journal Article
Closed access
Khaled E. AbuelellaKhaled E. Abuelella
Khaled E. Abuelella
SMShaimaa Mosallam
Shaimaa Mosallam
SSSara M. Soliman
Sara M. Soliman
AEAhmed Hassen Elshafeey
Ahmed Hassen Elshafeey
Licofelone (LF) is an analgesic drug with a unique pharmacological mechanism. It belongs to non-steroidal anti-inflammatory drugs (NSAIDs). However, it inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymes in the arachidonic acid metabolism pathway. It illustrated that it has superior efficacy compared to selective COX inhibition drugs. Dual COX/5-LOX inhibition exhibits potent anti-inflammatory and analgesic properties and fewer gastrointestinal side effects. Its therapeutic efficacy is primarily attributed to the suppression of proinflammatory prostaglandins (PGs) and leukotrienes (LTs), which are critical mediators in the pathogenesis of osteoarthritis. Furthermore, LF does not cause gastrointestinal side effects commonly associated with NSAIDs. Beyond its application in osteoarthritis management, LF has shown promising neuroprotective effects, attributed to its ability to regulate inflammatory cytokines, modulate the COX/5-LOX pathway, and influence immune responses. This review renders an updated comprehensive evaluation of LF, involving its physicochemical properties, Ultraviolet (UV)-Visible absorption spectroscopy, Fourier transform infrared (FTIR) spectroscopy, Differential Scanning Calorimetry (DSC), pharmacological profile, metabolic pathways, safety in gastrointestinal and cardiovascular systems, pharmacokinetics, toxicity, clinical applications, and therapeutic potential for targeting immune responses within the central nervous system (CNS). These studies consistently indicate that LF provides protective effects through the suppression of both COX/5-LOX pathways. This means supporting its potential in neuroprotection, osteoarthritis management, and so many other related diseases, in addition to low gastrointestinal tract (GIT) adverse reactions.

23 March 2026 in AAPS PharmSciTech
Verified
Journal Article
Open access
PDF file
Khaled E. AbuelellaKhaled E. Abuelella
Khaled E. Abuelella
SMShimaa Mosalm
Shimaa Mosalm
AEAmira A. El-Gazar
Amira A. El-Gazar
AEAhmed Elshafeey
Ahmed Elshafeey
SSSara M. Soliman
Sara M. Soliman
Irritant contact dermatitis (ICD) is a common and potentially debilitating chronic skin disorder that affects a large proportion of the worldwide populatio